Develops gene therapies for lung cancer and diabetes.
Dec 2024Revenue $0.00/yrExpenses $21.2M/yr
No trendCash runway ≈ 1.0 years from Jun 2026
Figures by year
When will Genprex be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Dec 2024, revenue was $0.00 and expenses $21.2M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2024 | $0.00 | $21.2M | −$21.2M |
| Dec 2023 | $0.00 | $31.1M | −$31.1M |
| Dec 2022 | $0.00 | $23.8M | −$23.8M |
| Dec 2021 | $0.00 | $20.7M | −$20.7M |
| Dec 2020 | $0.00 | $18.0M | −$18.0M |
| Dec 2018 | $0.00 | $12.4M | −$12.4M |
| Dec 2017 | $0.00 | $3.31M | −$3.31M |
| Dec 2016 | $0.00 | $4.13M | −$4.13M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.